l General Information |
Product Name | Dabrafenib |
General description | Dabrafenib is an orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. |
Synonym | N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6 difluorobenzenesulfonamide; GSK 2118436 |
Purity | ≥99.0%(HPLC) | CAS Number | 1195765-45-7 |
Formula | C23H20F3N5O2S2 | Molecular Weight | 519.56 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | White or Off-white solid |
Solubility(25℃) | DMSO | ≥25mg/mL |
Ethanol | Very slightly soluble |
Water | Insoluble |
l Biological Information |
Biochem/Physiol Actions | Dabrafenib is an orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations. |
Application | 1. Antineoplastic Agents Substances that inhibit or prevent the proliferation of neoplasms. 2. Protein Kinase Inhibitors Agents that inhibit Protein Kinases. |
l Packaging & Storage |
Packaging | 10mg; 25mg; 100mg; 500mg |
Storage temp. | -20℃ |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
